Showing results (951-960 of 980) with videos related to
Sort By:
Pageof 98
Nature Communications|March 19, 2025
Parity-dependent state transfer for direct entanglement generationF A Roy, J H Romeiro, L Koch, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 5, 2025
Cognitive and neuropsychological trajectories in patients with mixed neurodegenerative pathologiesFrancisco C Almeida, Gabriel A Marx, Susan K Rohde, et al.Blood|June 22, 2001
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosisS E Straus, E S Jaffe, J M Puck, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 1, 2023
Spatial proteomics of hippocampal subfield-specific pathology in Alzheimer's disease and primary age-related tauopathyJamie M Walker, Miranda E Orr, Timothy C Orr, et al.Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.Neurology|October 16, 2016
Progression of brain atrophy in PSP and CBS over 6 months and 1 yearShubir Dutt, Richard J Binney, Hilary W Heuer, et al.Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|October 7, 2018
Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPAMaria Luisa Mandelli, Ariane E Welch, Eduard Vilaplana, et al.Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.Journal of Medicinal Chemistry|November 2, 2011
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)Sean T Murphy, Gordon Alton, Simon Bailey, et al.Pageof 98